Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion
Rajeshwari Sridhara(Center for Drug Evaluation and Research), Bruce Binkowitz(Shionogi (United States)), Martin Posch(Medical University of Vienna), Yuan Li Shen, Lorenzo Hess, Scott Berry(Queen's University), Michael Coory(Government of Western Australia Department of Health), Qi Jiang(National Cancer Centre Japan), Olga Marchenko(Yaroslav Mudryi National Law University), Yevgen Tymofyeyev(Janssen (United States)), Richard H. Simon(University of Michigan), Richard Pazdur(United States Food and Drug Administration), Filip Josephson(Medical Products Agency), Andrew Raven, Marc R. Theoret(United States Food and Drug Administration), Naoto Kotani, Thomas Gwise(United States Food and Drug Administration), Xiaoyun Li(Nanjing University), Mary W. Redman(Fred Hutch Cancer Center), Kit C. B. Roes(Radboud University Nijmegen)
Cited by 12
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k